Evidence page · about 6 minutes

Semaglutide and tirzepatide: what the trials show

The two medicines most women ask about, side by side. Trial numbers, how strong each finding is, and what no trial has answered yet.

Reviewed by the Kenning clinical and outcomes research team · Updated November 2026

This page compares trial results. It doesn’t say which medicine is right for you. That depends on your health, your other medicines and your goals, so decide with your prescriber.

20.2% vs 13.7%

Average weight lost over 72 weeks on tirzepatide and on semaglutide, in the only head-to-head trial.

Aronne et al., SURMOUNT-5, NEJM 2025

The two medicines at a glance

Semaglutide

Tirzepatide

What it is

SemaglutideA GLP-1 medicine. It copies one gut hormone that tells the brain you are full.

TirzepatideA GIP and GLP-1 medicine. It copies two gut hormones.

Brand names

SemaglutideWegovy (weight), Ozempic (diabetes)

TirzepatideMounjaro, Zepbound

How it’s taken

SemaglutideOnce a week by injection. A daily pill (Wegovy, 25 mg) was approved in the US in December 2025.

TirzepatideOnce a week by injection

Dose steps

SemaglutideStarts at 0.25 mg. Goes up every 4 weeks to 2.4 mg by week 16.

TirzepatideStarts at 2.5 mg. Goes up 2.5 mg every 4 weeks, to 5, 10 or 15 mg.

In Hong Kong

SemaglutideRegistered. Wegovy launched November 2025.

TirzepatideRegistered for weight and diabetes, October 2024.

Heart outcomes

SemaglutideLowered heart attack, stroke and heart death by 20% in people with heart disease and no diabetes (SELECT).

TirzepatideMatched an older GLP-1 in people with diabetes and heart disease. A trial in people without diabetes is still running.

Weight lost in the trials

Average percent of starting weight lost. Bars on the same card can be compared. Bars on different cards came from different trials.

TirzepatideSemaglutidePlacebo

Head to head: the only direct comparison

SURMOUNT-5 · 751 adults without diabetes · 72 weeks · US

Strong
Tirzepatide (10 or 15 mg)20.2%
Semaglutide (1.7 or 2.4 mg)13.7%

Open-label and funded by the maker of tirzepatide. Each person took the highest dose she could tolerate.

Each medicine against placebo, worldwide

STEP 1 (68 weeks) and SURMOUNT-1 (72 weeks) · adults without diabetes

Strong
Tirzepatide 15 mg20.9%
Tirzepatide 5 mg15.0%
Semaglutide 2.4 mg14.9%
Placebo (SURMOUNT-1)3.1%
Placebo (STEP 1)2.4%

Two separate trials. They were run at different times with different people, so read them side by side with care.

Trials in East Asian adults

STEP 6 (Japan, Korea, 68 weeks) · SURMOUNT-J (Japan, 72 weeks) · SURMOUNT-CN (China, 52 weeks)

Strong
Tirzepatide 15 mg, Japan22.7%
Tirzepatide 15 mg, China17.5%
Semaglutide 2.4 mg, Japan and Korea13.2%
Placebo, range across trials2.3%

Each trial compared one medicine with placebo. The China trial was shorter, at 52 weeks. Placebo results ranged from 1.7% to 2.3%.

Two rulers

Where the line sits for Asian women, and where it’s the same for everyone.

Who the trials let in

General line

BMI 30

or 27 with a weight-related condition (STEP 1, SURMOUNT-1, SURMOUNT-5)

Asian line

BMI 28

or 24 with a weight-related condition (SURMOUNT-CN). Hong Kong counts obesity from BMI 25.

Asian women carry more health risk at a lower BMI. The trials in East Asia were designed around that.

Percent of weight lost

Same line for everyone

East Asian trials found losses in the same range as global trials: 13.2% on semaglutide, and 17.5% to 22.7% on tirzepatide 15 mg.

Side effects and stopping

Same line for everyone

The Japan trial reported a safety profile consistent with global trials. Regain after stopping hasn’t been studied in Asian women separately.

Side effects

Strong

Mostly nausea, diarrhea, constipation and vomiting. Most were mild to moderate and happened while the dose was going up.

Semaglutide

Tirzepatide

Any stomach or gut side effect, head to head

79.0%

76.7%

Nausea, against placebo

44% vs 17% on placebo (STEP 1)

25% to 33%, by dose (SURMOUNT-1)

Stopped because of side effects, against placebo

7.0% vs 3.1% on placebo

4.3% to 7.1% vs 2.6% on placebo

Head-to-head rates come from SURMOUNT-5. The other rows come from separate placebo trials.

Muscle

Mixed
Fat 60%Lean 40%

Semaglutide, STEP 1 scan study

Fat 75%Lean 25%

Tirzepatide, SURMOUNT-1 scan study

Part of the weight lost on both medicines is lean mass, which includes muscle. The share looked smaller with tirzepatide, but the two scan studies were small and separate.

Check your Mirror Four

Stopping

Strong

Two-thirds

of the lost weight came back within a year of stopping semaglutide (STEP 1 extension)

In SURMOUNT-4, people who switched from tirzepatide to placebo regained 14% of their weight over a year. Those who stayed on it lost another 5.5%.

Make a stopping plan

Menopause hormone therapy

Early

19.2% vs 14.0%

weight lost on tirzepatide with and without hormone therapy, in 120 women after menopause

A smaller study found the same pattern with semaglutide. These were record reviews, not trials, and most women were White. They can’t show that hormone therapy caused the extra loss.

GLP-1 and menopause

What the trials can’t tell you yet

  • Which one will work better for you. Averages hide a wide spread. Some people lose much more than average and some much less.
  • How Asian women in menopause do. No trial has reported results for this group on its own.
  • Whether tirzepatide protects the heart in people without diabetes. That trial is still running.
  • What happens after many years. Most trials ran 1 to 2 years.

Take to your appointment

Questions for your prescriber

  1. Given my health and other medicines, which would you choose for me, and why?
  2. What dose will I start on, and how fast will we go up?
  3. What should I do if the side effects are hard to manage?
  4. How will we protect my muscle while I lose weight?
  5. Does my menopause treatment change anything?
  6. If I stop one day, what’s our plan?
+ Where this comes from
  1. Aronne LJ, et al. Tirzepatide as compared with semaglutide for the treatment of obesity (SURMOUNT-5). NEJM, 2025.
  2. Wilding JPH, et al. Once-weekly semaglutide in adults with overweight or obesity (STEP 1). NEJM, 2021.
  3. Jastreboff AM, et al. Tirzepatide once weekly for the treatment of obesity (SURMOUNT-1). NEJM, 2022.
  4. Kadowaki T, et al. Semaglutide in an East Asian population (STEP 6). Lancet Diabetes & Endocrinology, 2022.
  5. SURMOUNT-J: tirzepatide in Japanese adults with obesity disease. Lancet Diabetes & Endocrinology, 2025; trial registry results.
  6. Zhao L, et al. Tirzepatide in Chinese adults with obesity (SURMOUNT-CN). JAMA, 2024.
  7. Wilding JPH, et al. Weight regain after withdrawal of semaglutide: STEP 1 extension. Diabetes, Obesity and Metabolism, 2022.
  8. Aronne LJ, et al. Continued tirzepatide for maintenance of weight reduction (SURMOUNT-4). JAMA, 2024.
  9. Lincoff AM, et al. Semaglutide and cardiovascular outcomes in obesity without diabetes (SELECT). NEJM, 2023.
  10. SURPASS-CVOT summary: tirzepatide vs dulaglutide in type 2 diabetes and heart disease. 2025.
  11. FDA approval of oral semaglutide 25 mg (Wegovy pill), OASIS 4. December 2025.
  12. Hurtado MD, et al. Menopausal hormone therapy and weight loss with semaglutide. Menopause, 2024.
  13. Castaneda R, et al. Hormone therapy and tirzepatide after menopause. Lancet Obstetrics, Gynaecology & Women’s Health, 2026.
  14. Hong Kong approval of tirzepatide, October 2024 and Wegovy launch in Hong Kong, November 2025.
  15. Nguyen N, Lu J. The Mirror and the Medicine. Kenning Health, 2027.

How we label strength: Strong means large randomized trials agree. Mixed means the studies point the same way but weren’t built to compare directly. Early means small or observational studies. Kenning provides education, not medical advice, diagnosis or treatment.